PT  - JOURNAL ARTICLE
AU  - Moghadas, Seyed M.
AU  - Fitzpatrick, Meagan C.
AU  - Shoukat, Affan
AU  - Zhang, Kevin
AU  - Galvani, Alison P.
TI  - Simulated identification of silent COVID-19 infections among children and estimated future infection rates with vaccination
AID  - 10.1101/2021.01.06.21249349
DP  - 2021 Jan 01
TA  - medRxiv
PG  - 2021.01.06.21249349
4099  - http://medrxiv.org/content/early/2021/02/26/2021.01.06.21249349.short
4100  - http://medrxiv.org/content/early/2021/02/26/2021.01.06.21249349.full
AB  - Importance A significant proportion of COVID-19 transmission occurs silently during the pre-symptomatic and asymptomatic stages of infection. Children, while being important drivers of silent transmission, are not included in the current COVID-19 vaccination campaigns.Objective To investigate the benefits of identifying silent infections among children as a proxy for their vaccination.Design This study used an age-structured disease transmission model, parameterized with census data and estimates from published literature, to simulate the synergistic effect of interventions in reducing attack rates over the course of one year.Setting A synthetic population representative of the United States (US) demographics.Participants Six age groups of 0-4, 5-10, 11-18, 19-49, 50-64, 65+ years based on US census data.Interventions In addition to the isolation of symptomatic cases within 24 hours of symptom onset, vaccination of adults was implemented to reach a 40%-60% coverage over the course of one year with an efficacy of 95% against symptomatic and severe COVID-19.Main Outcomes and Measures The combinations of proportion and speed for detecting silent infections among children which would suppress future attack rates below 5%.Results In the base-case scenarios with an effective reproduction number Re = 1.2, a targeted approach that identifies 11% and 14% of silent infections among children within 2 or 3 days post-infection, respectively, would bring attack rates under 5% with 40% vaccination coverage of adults. If silent infections among children remained undetected, achieving the same attack rates would require an unrealistically high vaccination coverage (at least 81%) of this age group, in addition to 40% vaccination coverage of adults. The effect of identifying silent infections was robust in sensitivity analyses with respect to vaccine efficacy against infection and reduced susceptibility of children to infection.Conclusions and Relevance In this simulation modeling study of a synthetic US population, in the absence of vaccine availability for children, a targeted approach to rapidly identify silent COVID-19 infections in this age group was estimated to significantly mitigate disease burden. Without measures to interrupt transmission chains from silent infections, vaccination of adults is unlikely to contain the outbreaks in the near term.Question What is the effect of a targeted strategy for identification of silent COVID-19 infections among children in the absence of their vaccination?Findings In this simulation modeling study, it was found that identifying 10-20% of silent infections among children within three days post-infection would bring attack rates below 5% if only adults were vaccinated. If silent infections among children remained undetected, achieving the same attack rate would require an unrealistically high vaccination coverage (over 80%) of this age group, in addition to vaccination of adults.Meaning Rapid identification of silent infections among children can achieve comparable effects as would their vaccination.Competing Interest StatementThe authors have declared no competing interest.Funding StatementCanadian Institutes of Health Research [OV4-170643, COVID-19 Rapid Research]; the National Institutes of Health [1RO1AI151176-01; 1K01AI141576-01], and the National Science Foundation [RAPID 2027755; CCF-1918784].Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Not required.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesN/A